There is no current evidence from randomised controlled trial to recommend any specific treatment for suspected or confirmed patients with COVID-19.
The interim findings of the trial in which the four drugs were tested in 405 hospitals across 30 countries, covering 11,266 adults, were released on 'medRxiv', a preprint server, on Thursday. The findings are under review for publication in a medical journal.
The ministry has removed its earlier recommendation of the use of anti-HIV drug combinations Lopinavir and Ritonavir on a case-to-case basis depending upon the severity of the condition of a patient suffering from coronavirus infection.
Cipla is among the three Indian companies that signed a non-exclusive licensing agreement with US-based Gilead Sciences to make and distribute the latter's repurposed Ebola drug Remdesivir in 127 countries including India.
The rate of doubling of COVID-19 cases has increased to 12.6 days
India has rejected a drug patent application of a United States multinational pharma company, paving the way for easy access to an important life-saving medication for HIV patients across the globe.
In Jaipur, the combination of lopinavir and ritonavir, both second-line HIV drugs, was administered was administered on an elderly Italian couple undergoing treatment for Covid-19 at the SMS Hospital.
A trial has shown that plasma therapy does not reduce mortality or prevent progression of COVID-19.
The global heath body had earlier suspended the hydroxychloroquine arm of the clinical trials of experimental COVID-19 drugs over safety concerns.
The country had the third-largest number of people living with disease.
